Health Care · Pharmaceutical Preparations

OGN Organon & Co SEC Filings & Insider Trading Activity 2026

company
CIK 182182571 filings

OGN at a glance

Organon & Co (OGN, SEC CIK 1821825) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on October 30, 2026, an 8-K current report on October 30, 2026 and Form 4 insider filings as recently as November 16, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Organon & Co (OGN) reported revenue of $6.2 billion (down 2.9% from FY2024) and net income of $187.0 million. Diluted EPS was $0.72.
  • As of September 30, 2026, 37 institutional investment managers tracked by SignalX reported holding Organon & Co (OGN) shares worth $1.4 billion in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$6.2B
−2.9% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
37 funds
$1.4B · +0 vs prior quarter
Latest 8-K
Oct 30, 2026
Item 7.01

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $1.574B, down 2% YoY, including approximately $12M favorable foreign exchange impact
  • Quarterly gross margin 61.2% vs 59.6% YoY, based on gross profit of $965M and revenue of $1.574B
  • Best product: Hadlima sales up 35% YoY; worst: Ontruzant sales down 77%
  • Cash $1.46B; nine-month operating cash flow $702M vs $559M YoY
  • Headwinds: supply constraints, Nexplanon demand weakness, VBP expected to continue affecting general medicines for several quarters

Risk Factors

  • Newly added patent risk: four Vtama generic ANDAs filed, targeting twelve or nine Orange Book patents expiring 2036–2039
  • Regulatory risk: SEC investigation into Nexplanon wholesaler sales, following Organon’s October 26, 2025 voluntary disclosure
  • Legal risk: third stockholder derivative suit filed September 19, 2026, adding allegations concerning capital allocation, debt reduction and Nexplanon
  • Operational risk: Samsung returned Ontruzant and Aybintio commercialization rights in specified ex-U.S. markets, with transitions through 2029
  • Financial risk: $8,554 million debt principal, including $3,483 million due in 2028 and average maturity of 3.8 years

AI summary of the OGN 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Oct 30, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q3 2026 adjusted net income $256M, down from $263M; adjusted diluted EPS $0.94 versus $1.01
  • Nine-month adjusted net income $674M, down from $789M; adjusted diluted EPS $2.51 versus $3.03

Item 7.01: Regulation FD Disclosure

  • Q3 2026 results covered quarter ended September 30, 2026, with GAAP disclosures in the Form 10-Q
  • Supplemental non-GAAP metrics furnished in Exhibit 99.1 for investor analysis alongside GAAP results
Filed Jul 31, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Q2 2026 results covered quarter ended June 30, 2026, with GAAP financials in Form 10-Q filed July 31, 2026
  • Quarterly earnings release and conference call suspended due to pending merger with Sun Pharmaceutical Industries

Item EX-99.1: Item EX-99.1

  • Q2 2026 adjusted net income $230M, down from $261M; adjusted diluted EPS $0.85 vs $1.00
  • Six-month adjusted EPS $1.57 vs $2.02, signaling weaker underlying earnings despite GAAP net income rising to $254M
Filed Jul 23, 2026Full analysis →

Item 5.07: Submission of Matters to a Vote of Security Holders

  • Merger agreement with Sun Pharma approved, clearing the key shareholder vote for Organon’s acquisition
  • 192,776,552 votes for versus 2,573,118 against, representing strong approval among votes cast

AI summaries of OGN 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for OGN

Don't miss the next OGN filing

  • Alerts as it files. A push when OGN files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut OGN, by share count.
  • Ask anything. An AI agent that reads every OGN filing and answers with sources.

OGN alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Morrissey Joseph T. Jr.MNov 13, 2026-
Drinane Juliana PapaMNov 13, 2026-
Drinane Juliana PapaMNov 13, 2026-
Morrissey Joseph T. Jr.FNov 13, 2026$13.90
Morrissey Joseph T. Jr.MNov 13, 2026-
Drinane Juliana PapaFNov 13, 2026$13.90
Holzbaur LynetteFNov 7, 2026$13.87
Holzbaur LynetteMNov 7, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$6.3B$6.4B$6.2B
Gross Profit$3.7B$3.7B$3.3B
Net Income$1.0B$864.0M$187.0M
Gross Margin59.8%58.0%53.3%
Net Margin16.3%13.5%3.0%
Balance Sheet
Total Assets-$13.1B$12.9B
Equity-$472.0M$752.0M
ROE-183.1%24.9%
Per Share
EPS$3.99$3.33$0.72
Cash Flow
Operating CF-$939.0M$700.0M
CapEx-$175.0M$162.0M

Source: XBRL data in Organon & Co (OGN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate OGN share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
OGN shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202637$1.36B
Q2 202637$1.33B
Q1 202639$699.0M
Q4 202534$837.3M
Q3 202535$1.17B
Q2 202536$1.15B
Q1 202531$1.06B
Q4 202429$876.0M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 278 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

OGN filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 16, 2026--
4Nov 16, 2026--
4Nov 10, 2026--
4Nov 10, 2026--
4Nov 10, 2026--
8-KOct 30, 2026Analysis-
10-QOct 30, 2026Analysis
4Aug 12, 2026--
4Aug 5, 2026--
8-KJul 31, 2026Analysis-
10-QJul 31, 2026-
8-KJul 23, 2026Analysis-
8-KJul 17, 2026Analysis-
4Jun 15, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
8-KJun 11, 2026--
4May 7, 2026-
4May 7, 2026-

Related Health Care companies

All Health Care →

OGN SEC filings: frequently asked questions

Which institutions hold OGN stock?

As of September 30, 2026, the largest Organon & Co (OGN) holders among the 13F filers tracked by SignalX were BlackRock ($437.3 million), Vanguard Portfolio Management LLC ($210.3 million), Vanguard Capital Management LLC ($163.3 million), State Street Corp ($133.7 million), Millennium Management ($70.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was OGN's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Organon & Co (OGN) reported revenue of $6.2 billion (down 2.9% from FY2024) and net income of $187.0 million. Diluted EPS was $0.72. The figures come from the XBRL data in the 10-K.

What did OGN report in its latest 8-K?

Organon & Co (OGN) filed an 8-K on October 30, 2026 reporting Item 7.01 (Regulation FD Disclosure). Q3 2026 adjusted net income $256M, down from $263M; adjusted diluted EPS $0.94 versus $1.01.

What are the latest OGN SEC filings?

Organon & Co (OGN) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on October 30, 2026, an 8-K current report on October 30, 2026 and a Form 4 insider filing on November 16, 2026.

What is OGN's SEC CIK number?

Organon & Co (OGN)'s SEC Central Index Key (CIK) is 1821825. EDGAR lists every OGN filing under that number.

Ask anything about OGN

The research agent reads OGN's filings, financials, insider trades and 13F holders, then answers with sources.